BioWorld Asia

May 8, 2002

GenOway Enters Drug Target Deal, Plans $5.4M Financing

PARIS - GenOway SA signed a nonexclusive agreement with the French pharmaceutical company Servier for the in vivo validation of a number of therapeutic gene targets. (BioWorld International Read More

EU Advisers Support Stem Cell Research, Cautious On Patents

Reprogramming Technique Raises Hopes Of Adult Skin Cell Therapy

Screentec Signals Discovery Ambitions With Name Change

Other News To Note

MMI Raises £1.6M In Placement To Finance Start-Ups, Incubators

Proteome Sciences’ Data Show Sensitivity, Specificity In Test

Personal Chemistry Purchases ESyTech To Extend Platform

Cerep Completes Drug Target Validation Under 1999 BMS Deal

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Brush scrubbing brain figurine with soap

PSB-229 reduces plaque burden in Alzheimer’s models

BioWorld Science

Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...